000155421 001__ 155421
000155421 005__ 20210129214105.0
000155421 0247_ $$2doi$$a10.1007/s11060-014-1595-y
000155421 0247_ $$2WOS$$aWOS:000345286700022
000155421 037__ $$aFZJ-2014-04587
000155421 082__ $$a610
000155421 1001_ $$0P:(DE-HGF)0$$aKickingereder, P.$$b0
000155421 245__ $$aLow-dose rate stereotactic iodine-125 brachytherapy for the treatment of inoperable primary and recurrent glioblastoma: single-center experience with 201 cases
000155421 260__ $$aDordrecht [u.a.]$$bSpringer Science + Business Media B.V$$c2014
000155421 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1416470595_16336
000155421 3367_ $$2DataCite$$aOutput Types/Journal article
000155421 3367_ $$00$$2EndNote$$aJournal Article
000155421 3367_ $$2BibTeX$$aARTICLE
000155421 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000155421 3367_ $$2DRIVER$$aarticle
000155421 520__ $$aTreatment options for inoperable glioblastoma are limited. Low-dose-rate stereotactic iodine-125 brachytherapy (SBT) has been reported as an effective and low-risk treatment option for circumscribed low-grade gliomas and brain metastases. The present study evaluates this treatment approach for patients with inoperable glioblastoma. Between 1990 and 2012, 201 patients with histologically proven glioblastoma were treated with SBT (iodine-125 seeds; median cumulative surface dose, 60 Gy; median dose-rate, 6 cGy/h; median gross-tumor-volume, 17 ml) either as primary treatment (n = 103) or at recurrence (n = 98). In addition to SBT, 90.3 % of patients in the primary treatment group received external boost radiotherapy (median dose, 25.2 Gy). Adjuvant chemotherapy was added for 30.8 % of patients following SBT and consisted of temozolomide for the majority of cases (88.7 %). Procedure-related complications, clinical outcome, progression-free and overall survival (PFS, OS) were evaluated. Median follow-up was 9.8 months. The procedure-related mortality was zero. During follow-up, transient and permanent procedure-related morbidity was observed in 7.5 and 2.0 %, respectively. Calculated from the time of SBT, median OS and PFS rates were 10.5 and 6.2 months, with no significant differences among primary and recurrent tumors (11.1 vs.10.4 months for OS and 6.2 vs. 5.9 months for PFS). For OS, multivariate analysis revealed Karnofsky performance score, age, and adjuvant chemotherapy as independent prognostic factors (all p < 0.01). Low-dose-rate SBT is a relatively safe and potentially effective local treatment option for patients with circumscribed inoperable glioblastoma initially or at recurrence. It deserves prospective validation since it may improve the outcome for a subset of patients with inoperable GBM.
000155421 536__ $$0G:(DE-HGF)POF2-333$$a333 - Pathophysiological Mechanisms of Neurological and Psychiatric Diseases (POF2-333)$$cPOF2-333$$fPOF II$$x0
000155421 536__ $$0G:(DE-HGF)POF2-89572$$a89572 - (Dys-)function and Plasticity (POF2-89572)$$cPOF2-89572$$fPOF II T$$x1
000155421 7001_ $$0P:(DE-HGF)0$$aHamisch, C.$$b1
000155421 7001_ $$0P:(DE-HGF)0$$aSuchorska, B.$$b2
000155421 7001_ $$0P:(DE-Juel1)143792$$aGalldiks, N.$$b3
000155421 7001_ $$0P:(DE-HGF)0$$aGoldbrunner, R.$$b4
000155421 7001_ $$0P:(DE-HGF)0$$aKocher, M.$$b5
000155421 7001_ $$0P:(DE-HGF)0$$aTreuer, H.$$b6
000155421 7001_ $$0P:(DE-HGF)0$$aVoges, J.$$b7
000155421 7001_ $$0P:(DE-HGF)0$$aRuge, M. I.$$b8$$eCorresponding Author
000155421 773__ $$0PERI:(DE-600)2007293-4$$a10.1007/s11060-014-1595-y$$n3$$p 615-623$$tJournal of neuro-oncology$$v120$$x0167-594x$$y2014
000155421 8564_ $$uhttps://juser.fz-juelich.de/record/155421/files/FZJ-2014-04587.pdf$$yRestricted
000155421 909CO $$ooai:juser.fz-juelich.de:155421$$pVDB
000155421 9101_ $$0I:(DE-588b)5008462-8$$6P:(DE-Juel1)143792$$aForschungszentrum Jülich GmbH$$b3$$kFZJ
000155421 9132_ $$0G:(DE-HGF)POF3-572$$1G:(DE-HGF)POF3-570$$2G:(DE-HGF)POF3-500$$aDE-HGF$$bPOF III$$lKey Technologies$$vDecoding the Human Brain$$x0
000155421 9131_ $$0G:(DE-HGF)POF2-333$$1G:(DE-HGF)POF2-330$$2G:(DE-HGF)POF2-300$$3G:(DE-HGF)POF2$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lFunktion und Dysfunktion des Nervensystems$$vPathophysiological Mechanisms of Neurological and Psychiatric Diseases$$x0
000155421 9131_ $$0G:(DE-HGF)POF2-89572$$1G:(DE-HGF)POF3-890$$2G:(DE-HGF)POF3-800$$3G:(DE-HGF)POF3$$4G:(DE-HGF)POF$$aDE-HGF$$bProgrammungebundene Forschung$$lohne Programm$$v(Dys-)function and Plasticity$$x1
000155421 9141_ $$y2014
000155421 915__ $$0StatID:(DE-HGF)0010$$2StatID$$aJCR/ISI refereed
000155421 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR
000155421 915__ $$0StatID:(DE-HGF)0110$$2StatID$$aWoS$$bScience Citation Index
000155421 915__ $$0StatID:(DE-HGF)0111$$2StatID$$aWoS$$bScience Citation Index Expanded
000155421 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection
000155421 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bThomson Reuters Master Journal List
000155421 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS
000155421 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline
000155421 915__ $$0StatID:(DE-HGF)0310$$2StatID$$aDBCoverage$$bNCBI Molecular Biology Database
000155421 915__ $$0StatID:(DE-HGF)0420$$2StatID$$aNationallizenz
000155421 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine
000155421 9201_ $$0I:(DE-Juel1)INM-3-20090406$$kINM-3$$lKognitive Neurowissenschaften$$x0
000155421 980__ $$ajournal
000155421 980__ $$aVDB
000155421 980__ $$aI:(DE-Juel1)INM-3-20090406
000155421 980__ $$aUNRESTRICTED